2017
Corrigendum to “Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma” (Hum Pathol 2016;57:116-25)
Weiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, Krogsgaard M, Osman I, Darvishian F. Corrigendum to “Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma” (Hum Pathol 2016;57:116-25). Human Pathology 2017, 63: 222. PMID: 28449825, DOI: 10.1016/j.humpath.2017.03.001.Peer-Reviewed Original Research
2016
Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts
Weiss SA, Han J, Darvishian F, Tchack J, Han SW, Malecek K, Krogsgaard M, Osman I, Zhong J. Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts. Journal Of Translational Medicine 2016, 14: 299. PMID: 27760559, PMCID: PMC5070187, DOI: 10.1186/s12967-016-1026-2.Peer-Reviewed Original ResearchConceptsMelanoma-specific survivalShorter melanoma-specific survivalHost immune responseImmune responseTCGA cohortAge groupsClinicopathologic featuresSurvival outcomesPatient cohortPrimary melanomaHost anti-tumor immune responseMelanoma diagnosisAnti-tumor immune responseMelanoma Cooperative GroupIndependent prognostic factorPopulation-based surveillanceEnd Results ProgramGreater prognostic impactMelanoma patient cohortTop upstream regulatorsYounger age groupsAge-related factorsBrisk TILsConclusionsOlder ageLymphocyte measurementsImmunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma
Weiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, Krogsgaard M, Osman I, Darvishian F. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma. Human Pathology 2016, 57: 116-125. PMID: 27473267, PMCID: PMC5706446, DOI: 10.1016/j.humpath.2016.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorCD3 ComplexDisease-Free SurvivalFemaleForkhead Transcription FactorsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryKaplan-Meier EstimateLeukocyte Common AntigensLymphocytes, Tumor-InfiltratingMaleMelanomaNeoplasm GradingPhenotypeProportional Hazards ModelsSkin NeoplasmsTime FactorsTreatment OutcomeConceptsAbsent tumor-infiltrating lymphocytesTumor-infiltrating lymphocytesBrisk tumor-infiltrating lymphocytesRecurrence-free survivalPrimary melanomaTIL gradeOverall survivalImmunologic heterogeneityPresence of TILsHost antitumor immune responseAntitumor immune responseImmune checkpoint regulatorsLymphocyte markers CD3T cell activation pathwaysEosin-stained sectionsGene expression profilesIndependent prognosticationLymphocyte compositionTIL countSurvival outcomesImproved prognosisPrognostic valueHistologic evaluationNonbriskImmune response
2015
Tumor infiltrating lymphocyte (TIL) classifications and association with survival in primary melanomas.
Weiss S, Han S, Vogelsang M, Krogsgaard M, Lui K, Shapiro R, Kirchhoff T, Darvishian F, Osman I. Tumor infiltrating lymphocyte (TIL) classifications and association with survival in primary melanomas. Journal Of Clinical Oncology 2015, 33: e20042-e20042. DOI: 10.1200/jco.2015.33.15_suppl.e20042.Peer-Reviewed Original Research